IMPACT OF EDARAVONE DEXBORNEOL TREATMENT ON NEUROLOGICAL FUNCTION, COGNITIVE FUNCTION, AND INFLAMMATORY-OXIDATIVE STRESS STATUS IN PATIENTS WITH ACUTE PROGRESSIVE CEREBRAL INFARCTION

IF 1.6 4区医学 Q4 PHARMACOLOGY & PHARMACY

FARMACIA Pub Date : 2025-06-29 DOI:10.31925/farmacia.2025.3.10

ZIJIAN FAN

{"title":"IMPACT OF EDARAVONE DEXBORNEOL TREATMENT ON NEUROLOGICAL FUNCTION, COGNITIVE FUNCTION, AND INFLAMMATORY-OXIDATIVE STRESS STATUS IN PATIENTS WITH ACUTE PROGRESSIVE CEREBRAL INFARCTION","authors":"ZIJIAN FAN","doi":"10.31925/farmacia.2025.3.10","DOIUrl":null,"url":null,"abstract":"Acute progressive cerebral infarction (APCI) is marked by worsening symptoms and neurological decline with high mortality.This study aimed to compare the clinical efficacy of edaravone (Eda) and edaravone dexborneol (Eda.B) in APCI treatment.Clinical data from 98 APCI patients were retrospectively analysed: 48 received Eda and 50 received Eda.B intravenously for 2 weeks.Hemorheological parameters, neurological and cognitive function (NIHSS, MoCA, BI), serum inflammatory and oxidative stress markers (IL-6, IL-17, IL-1, MMP-9, MDA, SOD, GSH-Px), and cerebral perfusion (MRI-based) were evaluated.Compared to Eda, Eda.B significantly reduced blood viscosity indices and erythrocyte sedimentation rate, improved NIHSS, MoCA, and BI scores, and favourably modulated inflammatory-oxidative markers.Eda.B also enhanced cerebral blood volume and flow, while reducing mean transit time and time to peak.The clinical efficacy rate was higher in the Eda.B group (96.0% vs. 83.3%,p < 0.05), with similar adverse reaction rates (16.0% vs. 25.0%,p > 0.05).In conclusion, Eda.B showed superior effectiveness in improving neurological and cognitive function, cerebral perfusion, and reducing inflammation and oxidative stress in APCI patients. RezumatInfarctul cerebral acut progresiv (APCI) se caracterizeaz prin agravarea rapid a simptomelor i declin neurologic accentuat, fiind asociat cu o mortalitate ridicat.Acest studiu a comparat eficiena clinic a edaravonei (Eda) i a edaravonei dexborneol (Eda.B) n tratamentul APCI.Au fost analizate retrospectiv datele clinice a 98 de pacieni, dintre care 48 au primit Eda i 50 Eda.B, intravenos, timp de dou sptmni.S-au evaluat parametrii hemoreologici, funciile neurologice i cognitive (NIHSS, MoCA, BI), markerii serici inflamatori i de stres oxidativ (IL-6, IL-17, IL-1, MMP-9, MDA, SOD, GSH-Px), precum i perfuzia cerebral pe baza RMN.Comparativ cu Eda, Eda.B a redus semnificativ vscozitatea sngelui i viteza de sedimentare a hematiilor, a mbuntit scorurile funcionale i a reglat favorabil markerii inflamatori i de stres oxidativ.De asemenea, Eda.B a crescut volumul i fluxul sanguin cerebral, reducnd timpul mediu de tranzit.Rata de eficien clinic a fost mai mare n grupul Eda.B (96,0% vs. 83,3%, p < 0,05), fr diferene semnificative n privina reaciilor adverse.n concluzie, Eda.B s-a dovedit mai eficient n ameliorarea funciilor neurologice i cognitive, a perfuziei cerebrale i n reducerea inflamaiei i stresului oxidativ la pacienii cu APCI.","PeriodicalId":12344,"journal":{"name":"FARMACIA","volume":"73 3","pages":"637-645"},"PeriodicalIF":1.6000,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://farmaciajournal.com/wp-content/uploads/art-10-Fan_Mao_637-645.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.31925/farmacia.2025.3.10","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Acute progressive cerebral infarction (APCI) is marked by worsening symptoms and neurological decline with high mortality.This study aimed to compare the clinical efficacy of edaravone (Eda) and edaravone dexborneol (Eda.B) in APCI treatment.Clinical data from 98 APCI patients were retrospectively analysed: 48 received Eda and 50 received Eda.B intravenously for 2 weeks.Hemorheological parameters, neurological and cognitive function (NIHSS, MoCA, BI), serum inflammatory and oxidative stress markers (IL-6, IL-17, IL-1, MMP-9, MDA, SOD, GSH-Px), and cerebral perfusion (MRI-based) were evaluated.Compared to Eda, Eda.B significantly reduced blood viscosity indices and erythrocyte sedimentation rate, improved NIHSS, MoCA, and BI scores, and favourably modulated inflammatory-oxidative markers.Eda.B also enhanced cerebral blood volume and flow, while reducing mean transit time and time to peak.The clinical efficacy rate was higher in the Eda.B group (96.0% vs. 83.3%,p < 0.05), with similar adverse reaction rates (16.0% vs. 25.0%,p > 0.05).In conclusion, Eda.B showed superior effectiveness in improving neurological and cognitive function, cerebral perfusion, and reducing inflammation and oxidative stress in APCI patients. RezumatInfarctul cerebral acut progresiv (APCI) se caracterizeaz prin agravarea rapid a simptomelor i declin neurologic accentuat, fiind asociat cu o mortalitate ridicat.Acest studiu a comparat eficiena clinic a edaravonei (Eda) i a edaravonei dexborneol (Eda.B) n tratamentul APCI.Au fost analizate retrospectiv datele clinice a 98 de pacieni, dintre care 48 au primit Eda i 50 Eda.B, intravenos, timp de dou sptmni.S-au evaluat parametrii hemoreologici, funciile neurologice i cognitive (NIHSS, MoCA, BI), markerii serici inflamatori i de stres oxidativ (IL-6, IL-17, IL-1, MMP-9, MDA, SOD, GSH-Px), precum i perfuzia cerebral pe baza RMN.Comparativ cu Eda, Eda.B a redus semnificativ vscozitatea sngelui i viteza de sedimentare a hematiilor, a mbuntit scorurile funcionale i a reglat favorabil markerii inflamatori i de stres oxidativ.De asemenea, Eda.B a crescut volumul i fluxul sanguin cerebral, reducnd timpul mediu de tranzit.Rata de eficien clinic a fost mai mare n grupul Eda.B (96,0% vs. 83,3%, p < 0,05), fr diferene semnificative n privina reaciilor adverse.n concluzie, Eda.B s-a dovedit mai eficient n ameliorarea funciilor neurologice i cognitive, a perfuziei cerebrale i n reducerea inflamaiei i stresului oxidativ la pacienii cu APCI.

查看原文本刊更多论文

依达拉奉右冰片治疗对急性进展性脑梗死患者神经功能、认知功能和炎症氧化应激状态的影响

急性进行性脑梗死（APCI）的特点是症状恶化和神经功能下降，死亡率高。本研究旨在比较依达拉奉（Eda）与依达拉奉dexborneol （Eda. b）治疗APCI的临床疗效。回顾性分析98例APCI患者的临床资料：48例接受Eda治疗，50例接受Eda治疗。B静脉注射2周。评估血液流变学参数、神经和认知功能（NIHSS、MoCA、BI）、血清炎症和氧化应激标志物（IL-6、IL-17、IL-1、MMP-9、MDA、SOD、GSH-Px）和脑灌注（mri）。比起Eda， Eda。B可显著降低血液粘度指数和红细胞沉降率，改善NIHSS、MoCA和BI评分，并有利地调节炎症-氧化标志物，eda .B还可增加脑血容量和流量，同时减少平均过境时间和峰值时间。Eda组的临床有效率较高。B组不良反应发生率（96.0% vs. 83.3%,p < 0.05），两组不良反应发生率相似（16.0% vs. 25.0%,p < 0.05）。总之，Eda。B在改善APCI患者的神经功能和认知功能、脑灌注、减轻炎症和氧化应激方面表现出优越的疗效。急性进行性脑梗死（APCI）是一种以面积迅速增大、单纯性脑梗死为特征的疾病，其特点是神经系统重音下降，与死亡风险相关。最近的一项研究比较了依达拉沃尼（Eda）和依达拉沃尼dexborneol （Eda. b）治疗APCI的临床疗效。回顾性分析了98例患者的临床资料，48例患者的中心护理资料和50例患者的临床资料。B、静脉滴注、静脉滴注。S-au评价血液流变学、功能神经学、认知学（NIHSS、MoCA、BI）、标志物、炎性指标、应激氧化指标（IL-6、IL-17、IL-1、MMP-9、MDA、SOD、GSH-Px）、缺血、脑缺血等参数。比较而言，Eda, Eda。B一个redus semnificativ vscozitatea sngelui我viteza de sedimentare hematiilor,一个mbuntit scorurile funcionale我reglat favorabil markerii inflamatori我德度假oxidativ。祝你好运，爱达。脑出血呈新月形，体积大，流动性强，脑出血减少。低效率的临床试验是一种有效的临床试验。B (96,0% vs. 83,3%, p < 0.05)，对于不同意义的不良反应。总而言之，爱达。研究表明，它能有效改善认知功能区神经功能，改善大脑功能，减少炎症，减少氧化，改善APCI。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

FARMACIA 医学-药学

CiteScore

2.40

自引率

50.00%

发文量

审稿时长

6-12 weeks

期刊介绍： FARMACIA publishes original research papers, invited topical reviews and editorial commentaries and news, with emphasis on conceptual novelty and scientific quality. Main research areas are focused on: pharmacology, toxicology, medicinal chemistry, biopharmacy, drug design, drug delivery, personalized medicine, nanostructures, nutraceuticals, biochemistry and biotechnology. Manuscripts submitted to the Journal are only accepted after the peer review precess. The papers should have not been published in any other journal. The recommendations of the Declaration of Helsinki, for humans, and the International guidelines as accepted principles for the use of experimental animals should be followed.